Tesamorelin and Ipamorelin are both synthetic peptides that stimulate the release of growth hormone. However, they do this in different ways. This blog post explains what they are, their mechanism of action, their effects, and where you can purchase these USA made peptides.

WHAT IS TESAMORELIN

Tesamorelin is also known as (TH9507). It is a synthetic agonist of growth hormone-releasing factor that stimulates the production and release of endogenous growth hormone. It consists of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group. It is also potent and more stable than GHRH and is resistant to cleavage by the dipeptidyl aminopeptidase enzyme.

Tesamorelin was found to reduce triglycerides and total cholesterol levels in test subjects with lipodystrophy associated with antiretroviral therapy of HIV infection. Tesamorelin is also being evaluated as therapy of insulin resistance, obesity, and nonalcoholic fatty liver.

Its empirical formula is C₂₂₁H₃₆₆N₇₂O₆₇S, with a molecular weight of 5136 g/mol.

MECHANISM OF ACTION

Tesamorelin activates GHRH receptors in the pituitary, which leads to synthesis and release of growth hormone releasing-hormone that acts on multiple cells of the body, including hepatocytes, where it stimulates the production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates many of the effects of growth hormone, which in the liver include growth, inhibition of programmed cell death, glucose intolerance, and lipolysis.

WHAT IS IPAMORELIN

Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties with potency and efficacy similar to GHRP-6. Ipamorelin stimulates GH release through a GHRP-like receptor. Surprisingly, it does not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. Making ipamorelin the first GHRH agonist specific for GH release similar to that displayed by GHRH.

Its empirical formula is C₃₈H₄₉N₉O₅, and the molecular weight is 711.9 g/mol.

MECHANISM OF ACTION

Ipamorelin acts in a completely different way to stimulate growth hormone release. It binds to ghrelin receptors on the pituitary gland with no effect on the rest of the body’s hormones. Ghrelin has profound regulatory effects on metabolism, including increasing or decreasing hunger, inhibiting stored fat breakdown, and most importantly, the release of growth hormone from the pituitary gland.

EFFECTS OF TESAMORELIN AND IPAMOLERIN

Clinical studies show that tesamorelin and ipamorelin peptides don’t affect other pituitary hormones such as thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH), and prolactin.

Tesamorelin causes elevated IGF-1 levels, glucose intolerance, hypersensitivity reactions, among others. Ipamorelin’s possible side effects are similar to those of tesamorelin.

Some of the benefits of tesamorelin are related to the breakdown of lipids and triglycerides, which include a reduction in triglyceride levels, visceral adipose tissue, and the size of the carotid blood vessel. The benefits of ipamorelin also include improvement with inflammation, anti-aging properties, and reduced appetite, which leads to faster weight loss.

BUY TESAMORELIN OR IPAMORELIN

Tesamorelin and ipamorelin are available at Loti Labs for your research. We stock the highest quality USA-made peptides that are tested through HPLC and mass spectrometry. Buy peptides from us today!

References:

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/

2. Patel A, Gandhi H, Upaganlawar A. Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. 2011;3(2):319–320. doi:10.4103/0975-7406.80763

3. Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253–2259. doi:10.1097/QAD.0000000000001614

4. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149–155. Published 2012 Oct 19. doi:10.2147/JEP.S35396

5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552

6. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts the glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266–272. doi:10.1054/ghir.2001.0239